Search Results
Your search for ASCO,ASCO matches 21405 pages
Showing 501 - 550Trends in Cancer Incidence and Mortality in Appalachia
Investigators have found that although fewer patients may be diagnosed with and dying from cancer in Appalachia, cancer incidence and mortality rates remain substantially higher compared with elsewhere in the United States, according to a recent study published by Burus et al in the Journal of the...
Using AI to Identify Treatment Options for Castleman Disease
A novel artificial intelligence (AI) tool uncovered an effective treatment for a patient with idiopathic multicentric Castleman’s disease, according to a recent study published by Mumau et al in The New England Journal of Medicine. Background Idiopathic multicentric Castleman’s disease is a rare...
Novel Personalized Cancer Vaccine May Be Effective in Patients With Stage III and IV Clear Cell Renal Cell Carcinoma
Patients with stage III or IV clear cell renal cell carcinoma may have achieved a successful anticancer immune response following initiation of a novel personalized cancer vaccine, according to a recent study published by Braun et al in Nature. Background The standard treatment for stage III or IV...
New Study Identifies Potential Genes Implicated in Treatment-Resistant Melanoma
Researchers have found that inhibiting the S6K2 gene could be an effective strategy for managing treatment-resistant melanoma, according to a recent study published by Lipchick et al in Science Translational Medicine. Background Cases of melanoma—the deadliest type of skin cancer—are currently...
FDA Approves Preparative Regimen for Allogeneic HSCT in Patients With AML or MDS
On January 21, the U.S. Food and Drug Administration (FDA) approved treosulfan (Grafapex), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia ...
Is Thyroid Cancer Overdiagnosed?
A retrospective study provides new evidence that thyroid cancer continues to be overdiagnosed and that aggressive screening and treatment of thyroid cancer has not led to higher survival rates. The research was published by Chen et al in The Lancet Diabetes & Endocrinology. “Many studies have...
Is Clonal Cytopenia of Undetermined Significance Distinct From Lower-Risk Myelodysplastic Syndrome?
High-risk patients with clonal cytopenia of undetermined significance have very similar characteristics and outcomes as patients with lower-risk myelodysplastic syndrome (MDS), which can be informative with regard to prognosis, management, and clinical trial eligibility, said Zhuoer (Zoey) Xie, MD, ...
CAR T-Cell Therapy Not Linked to Secondary Cancers, Study Finds
Researchers have found no evidence that chimeric antigen receptor (CAR) T-cell therapy caused secondary cancers in the modified T cells, according to a recent study published by Jadlowsky et al in Nature Medicine. Background CAR T-cell therapy is a personalized type of immunotherapy that employs...
Potential Link Between Early Side Effects From Radiation Therapy and Long-Term Side Effects in Patients With Prostate Cancer
The risk of developing more serious long-term urinary and bowel health issues may be higher in men undergoing radiation therapy for prostate cancer who experience side effects early in treatment, according to a recent study published by Nikitas et al in The Lancet Oncology. The findings highlighted ...
Results From FIRE-4 Show Liquid Biopsy Can Detect RAS/BRAF-Mutated Metastatic Colorectal Cancer
The results from the phase III FIRE-4 randomized clinical trial show that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type–mutated metastatic colorectal cancer. The findings confirm the high clinical relevance of liquid biopsy performed at baseline before the start of...
AI May Boost Efficacy of Cancer Care, but Physicians Remain Critical to Decision-Making, Study Finds
Although artificial intelligence (AI)-assisted radiotherapy may help physicians make more informed decisions when treating patients with cancer, there may be challenges in how physicians work with the technology, according to a recent study published by Niraula et al in Nature Communications. Study ...
Neoadjuvant Radiotherapy May Hamper Immunotherapy Response in Patients With Breast Cancer
Researchers have provided novel insights into the effects of radiation on the immune cells surrounding breast cancer tumors, according to a recent study published by Yoneyama et al in the International Journal of Radiation Oncology • Biology • Physics. The findings revealed that the relationship...
FDA Approves First Companion Diagnostic to Identify Patients With Metastatic Breast Cancer Eligible for T-DXd
The U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone receptor (HR)-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with fam-trastuzumab...
Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL?
Late relapse of diffuse large B-cell lymphoma (DLBCL) may represent a new lymphoma arising from a common precursor cell that is essentially chemotherapy-naive. Treatment with curative intent using a second-line regimen like R-CHOP (rituximab cyclophosphamide, doxorubicin, prednisone, and...
Predicting Response to KRAS G12C Inhibitors in NSCLC
Researchers may have uncovered a novel strategy to help predict how well patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) will respond to new therapies, according to a recent study published by Kato et al in Clinical Cancer Research. Study Methods and Results Researchers developed ...
Rising Advanced Prostate Cancer Rates in California Follow Changes to Recommendations
The incidence of advanced prostate cancer rose and the mortality rate plateaued in most regions across the state of California following the decision to cease routinely screening all men for the disease, according to a recent study published by Van Blarigan et al in JAMA Network Open. The findings...
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
Chemotherapy Linked to Chronic Neuropathy for 4 in Every 10 Patients: Global Analysis Results
Worldwide, cancer chemotherapy is linked to chronic painful neuropathy for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the available evidence published by D’Souza et al in Regional Anesthesia & Pain Medicine. Notwithstanding wide regional...
Cancer Symptoms Mistaken for Pregnancy Symptoms Could Lead to Delays in Cancer Diagnosis
Misdiagnosing cancer symptoms as normal pregnancy-related changes among pregnant individuals could lead to delays in treatment, according to a recent study published by Marcu et al in the British Journal of General Practice. Study Methods and Results In the study, researchers recruited 20 women...
Salpingectomy During Other Abdominal Surgeries May Lower Ovarian Cancer Risk
Fallopian tube removal performed during other abdominal surgeries could reduce the risk of ovarian cancer incidence among women who have already completed their families, according to a recent study published by Kather et al in PLOS Medicine. Background Ovarian cancer is the third most common...
Hereditary Ovarian Cancer Risk: Unlocking New Insights
Researchers have uncovered new heredity genes that may contribute to an increased risk of developing high-grade serous ovarian cancer, according to a recent study published by Subramanian et al in npj Genomic Medicine. Background High-grade serous ovarian cancer is one of the most prevalent and...
Does Brain MRI Surveillance Benefit Asymptomatic Patients With Stage IV Breast Cancer?
Researchers have found that asymptomatic brain metastases may be more common in patients with stage IV breast cancer than previously understood, according to a recent study published by Ahmed et al in Neuro-Oncology. The findings suggest that physicians may need to reconsider current screening...
CheckMate 7FL: Neoadjuvant Immunochemotherapy in ER-Positive, HER2-Negative Breast Cancer
A phase III trial has shown adding the PD-1 inhibitor nivolumab to anthracycline- and taxane-based chemotherapy that patients receive ahead of surgery may improve breast cancer cure rates. CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer,...
Expediting Cancer Diagnoses With Acoustofluidics?
A novel system using standing surface acoustic waves may effectively and precisely separate circulating tumor cells from red blood cells, according to a novel study published by Kouhkord and Naserifar in the Physics of Fluids. Background Cancer accounted for nearly 10 million deaths in 2020—nearly...
Talimogene Laherparepvec May Effectively Reduce Basal Cell Carcinoma Size Prior to Surgical Resection
Treatment with the oncolytic virus talimogene laherparepvec may be effective in patients with basal cell carcinoma, according to a novel study published by Ressler et al in Nature Cancer. Background Although basal cell carcinoma—which typically occurs in chronically sun-exposed areas such as the...
Fecal Microbiota Transplantation Following ASCT
Oral fecal microbiota transplantation may be a feasible and safe option to prevent graft-vs-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant (ASCT), according to a recent report published by Reddi et al in Nature Communications. The findings built on ...
BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis
The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) ...
Anna Martling, MD, PhD, on the ALASCCA Trial in Colorectal Cancer
The randomized, double-blind, multicenter, placebo-controlled ALASCCA Trial screened 3,508 patients across 33 hospitals in Sweden, Denmark, Finland, and Norway for eligibility. They either had stage II or III colon cancer or stage I, II, or III rectal cancer. Ultimately, 626 patients continued on...
FDA Highlights Importance of DPD Deficiency Discussions With Patients Prior to Capecitabine or Fluorouracil Treatment
The U.S. Food and Drug Administration (FDA) has provided a safety announcement to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil related to the risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Background Fluoropyrimidines are a...
Cathy Eng, MD, on the FRESCO-2 Study in Metastatic Colorectal Cancer
Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, reported on findings from the FRESCO-2 study, focusing on overall survival with fruquintinib vs placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer (Abstract 171). Abstract 171, a...
UICC‘s New World Cancer Day Campaign Calls for Fundamental Shift in Cancer Care Delivery
The Union for International Cancer Control (UICC) has introduced the new 2025 to 2027 United by Unique campaign, calling for a fundamental shift in cancer care and health systems across the world toward a people-centered approach in light of World Cancer Day. World Cancer Day takes place on...
Young Patients With Cancer Living in Historic Redlined Neighborhoods Are Dying at Higher Rates Than Those in Nonredlined Areas
Studies have shown that adults living in historically redlined neighborhoods are less likely to be screened for breast, colorectal, and cervical cancers and have worse survival than those living in nonredlined areas. Redlining, a discriminatory, racist practice that began in the 1920s and 1930s in...
T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ...
Pinpointing Contributing Factors in Response to Posttransplant Donor Lymphocyte Infusion in Patients With AML
Researchers have identified factors that could determine whether donor lymphocyte infusion—a type of adoptive cell therapy—will result in remission among patients with acute myeloid leukemia (AML) who have relapsed following allogeneic hematopoietic stem cell transplant (HSCT), according to a...
Anatomic Lung Resection May Be Linked to Improved Survival in Early-Stage NSCLC
Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival in patients with early-stage non–small cell lung cancer (NSCLC) compared with wedge resection, according to new findings presented at the 2025 Society of Thoracic Surgeons (STS) Annual...
Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer
First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) chemotherapy regimen may be effective in patients with BRAF V600E–mutated metastatic colorectal cancer, according to recent findings presented by Kopetz et ...
Scott Kopetz, MD, PhD, FACP, on the BREAKWATER Study in BRAF V600–Mutant Metastatic Colorectal Cancer
The open-label, global, randomized phase III BREAKWATER study was an analysis of first-line encorafenib plus cetuximab plus chemotherapy in patients with BRAF V600E–mutant metastatic colorectal cancer. Here, Scott Kopetz, MD, PhD, FACP, of The University of Texas MD Anderson Cancer Center, reports ...
New Findings on Aspirin and Risk of Colorectal Cancer Recurrence
According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily after treatment ends may reduce the risk of cancer recurrence in patients with cancers that harbor a PI3K mutation. These mutations are common to many types ...
New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer
Previous research has shown that nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors, may reduce the risk of developing colon cancer. A recent CALGB/SWOG study revealed that adding celecoxib to FOLFOX chemotherapy improved disease-free survival in patients with...
Susumu Hijioka, MD, on the Phase III STARTER-NET Study in GEP-NET
Susumu Hijioka, MD, of the National Cancer Center, Tokyo, discusses results from the phase III JCOG1901 STARTER-NET study in patients with gastroenteropancreatic neuroendocrine (GEP-NET) tumors. The study evaluated combination therapy with everolimus plus lanreotide vs everolimus monotherapy for...
Thierry André, MD, on First Results From CheckMate 8HW
Thierry André, MD, of Hôpital Saint-Antoine, presented first results from the ongoing phase III CheckMate 8HW trial comparing nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract LBA143).
EULAR: Balancing Treatment Risks for Inflammatory Arthritis and Cancer
The European Alliance of Associations for Rheumatology (EULAR) introduced new points to consider surrounding the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer, according to recent recommendations published by Sebbag et al in the Annals of the...
Aasma Shaukat, MD, MPH, on A Blood-Based Test for Colorectal Cancer Screening
Aasma Shaukat, MD, MPH, of NYU Langone, presented results from the PREEMPT CRC study, which evaluated the clinical performance of an investigational blood-based screening test for detecting molecular signals of advanced colorectal neoplasia in an average-risk population (Abstract 18).
New Study Highlights Financial Burden of Medical Equipment on Cancer Survivors
Investigators may have uncovered the financial burden of different medical services on cancer survivors, according to a recent study published by Jafri et al in JAMA Network Open. Background Although the economic challenges faced by patients with cancer as a result of health-care costs are well...
Muscular Strength, Cardiorespiratory Fitness May Be Linked to Lower Risk of Mortality in Patients With Cancer
Muscular strength and cardiorespiratory fitness may be associated with a lower risk of all-cause mortality in patients with cancer, according to a recent study published by Bettariga et al in the British Journal of Sports Medicine. The findings indicated that a tailored exercise regimen may improve ...
Getting a Lung Cancer Diagnosis Was Shocking
For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...
2.83% Medicare Physician Reimbursement Cut Finalized for 2025; Estimated 4% Cut for Medical Oncology
Late in 2024, the Centers for Medicare & Medicaid Services (CMS) issued the 2025 Physician Fee Schedule (PFS) final rule adopting changes for Medicare payments under the PFS. CMS also released the 2025 Hospital Outpatient Prospective Payment System final rule, which sets hospital outpatient...
AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma
Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer,...
Genomic Classifier Tests May Influence Treatment Decisions in Prostate Cancer Despite Lack of Evidence for Long-Term Outcomes
Although genomic classifier tests may influence risk classifications or treatment decisions in patients with localized prostate cancer, there is a need for more data to better understand cost effectiveness, clinical utility, and their impact on racial and ethnic groups—particularly Black men,...
